Andexanet alfa for the reversal of factor Xa inhibitors
Expert Opinion on Biological Therapy, 2019 Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-threatening or uncontrolled bleeding.
Sarah Lessire +2 more
exaly +5 more sources
Related searches:
Real-world utilization of andexanet alfa
American Journal of Emergency Medicine, 2020In 2018, the FDA approved andexanet alfa for the reversal of life-threatening hemorrhages in patients anticoagulated with apixaban or rivaroxaban. Yet, cost-effective factor Xa inhibitor reversal remains controversial. The objective of this study was to describe real world utilization of andexanet alfa.This was a retrospective case series of patients ...
Meera Sridharan, Caitlin S Brown
exaly +5 more sources
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
New England Journal of Medicine, 2019 Background Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa ...
Peter Verhamme +2 more
exaly +3 more sources
Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors — Individual patient data analysis of ANNEXA-4 and TICH-NOAC [PDF]
International Journal of StrokeBackground: Data comparing the specific reversal agent andexanet alfa with non-specific treatments in patients with non-traumatic intracerebral hemorrhage (ICH) associated with factor-Xa inhibitor (FXaI) use are scarce.
Martina Goeldlin +2 more
exaly +3 more sources
Andexanet alfa for the treatment of hemorrhage
Expert Review of Hematology, 2018While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians.
Andrea Cervi, Mark Crowther
exaly +3 more sources
Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy [PDF]
Stroke, 2021 Contains fulltext : 245685.pdf (Publisher’s version ) (Open Access)BACKGROUND AND PURPOSE: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to reverse FXa inhibition from anticoagulants.
Peter Verhamme +2 more
exaly +4 more sources
Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation
Expert Review of Hematology, 2016 Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The molecule is a recombinant protein analog of factor Xa that binds to Factor Xa inhibitors and antithrombin:LMWH complex but does not trigger prothrombotic activity.
Ian Welsby
exaly +2 more sources
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study [PDF]
Research and Practice in Thrombosis and Haemostasis, 2023 BACKGROUND: Well-designed studies with sufficient sample size comparing andexanet alfa vs 4-factor prothrombin complex concentrate (4F-PCC) in routine clinical practice to evaluate clinical outcomes are limited.
Danese, Sherry +23 more
exaly +2 more sources